On the other hand, although experimental in vitro and in vivo studies have shown that paricalcitol may have anti-inflammatory properties, clinical data are limited [13–15] and no studies have been performed to analyze the effects of selective vitamin D receptor activation as a target for modulate inflammation in patients with CKD before the initiation of dialysis treatment. This evidence concerns the gene VDR and chronic kidney disease.